Publications by authors named "A Wicky"
Article Synopsis
- Anti-PD-1 antibodies and BRAF/MEK inhibitors can help reduce recurrence risk in resected stage III melanoma patients, and the study investigated the effectiveness of a 'second adjuvant' BRAF/MEKi therapy for those who experienced recurrence after initial treatment.
- A total of 73 BRAFmut melanoma patients were analyzed, with 61 receiving 'second adjuvant' therapy and showing significant improvements in recurrence-free survival (RFS) compared to those who didn’t receive this treatment.
- While the second adjuvant therapy led to better RFS, it also resulted in high rates of toxicity, prompting a need for further research on treatment strategies to enhance outcomes while minimizing side effects.
Importance: Acral (AM) and mucosal melanomas (MM) are rare subtypes with a poor prognosis. In those with advanced disease, anti-PD-1 (PD1) therapy has reduced activity compared to that seen in non-acral cutaneous melanoma.
Objective: To determine the efficacy of adjuvant PD1 in resected AM or MM.
Article Synopsis
- The combination therapy of nivolumab and relatlimab shows better results than nivolumab alone for treating naive melanoma patients; patients with type 2 diabetes were noted to have reduced LAG3 expression in tumor tissues.
- A multicenter retrospective study involved 129 patients, comparing those without diabetes, those with type 2 diabetes, and those who developed immune checkpoint inhibitor-induced diabetes (ICI-DM) during treatment.
- Findings indicated that patients without diabetes had longer progression-free survival (PFS) and overall survival (OS) than those with type 2 diabetes, while patients who developed ICI-DM had the best outcomes, highlighting the impact of glucose levels on prognosis.
Objectives: The objective of this study is the exploration of Artificial Intelligence and Natural Language Processing techniques to support the automatic assignment of the four Response Evaluation Criteria in Solid Tumors (RECIST) scales based on radiology reports. We also aim at evaluating how languages and institutional specificities of Swiss teaching hospitals are likely to affect the quality of the classification in French and German languages.
Methods: In our approach, 7 machine learning methods were evaluated to establish a strong baseline.
The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy but only a fraction of patients benefits from this therapy. Model-informed drug development can be used to assess prognostic and predictive clinical factors or biomarkers associated with treatment response. Most pharmacometric models have thus far been developed using data from randomized clinical trials, and further studies are needed to translate their findings into the real-world setting.
View Article and Find Full Text PDF